Research Reveals Pharma Profits Outweigh Anti-Kickback Penalties (opens in new tab)

The pharmaceutical industry has a well documented history of corruption and placing profit above public health. A new research letter published in JAMA Open finds that US revenues from drugs involved in kickback settlements far surpassed the penalties. This research, led by Tobias Liu from Yale University, also reports many major pharmaceutical companies, including Pfizer, […] The post Research Reveals Pharma Profits Outweigh Anti-Kickback Penalties appeared first on Mad In America.